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We analyzed gp120V3 HIV-1 env region genetic diversity of 27 patients failing antiretrovirals and subjected to 12-week structured treatment
interruption (STI). Based on heteroduplex mobility assays, eight patients presented low pre- and post-STI genetic diversity (G1); five presented
high pre-STI but low post-STI diversity (G2); five presented low pre-STI and high post-STI diversity (G3); and nine, high pre- and post-STI
diversity (G4). One patient from G1, two from G2 and two from G3 were subjected to proviral DNA end-point PCR and sequencing. In three
patients, the dramatic disturbance caused by STI resulted in ancestral viral progeny activation, which repopulated the cell reservoir. In two patients
presenting highly homogeneous sequences and low immune selective pressure (dN/dS ratio <1), this phenomenon was not observed. The
mechanisms involved in viral evolution, in which antiretroviral therapy also applies selective pressure, sometimes affects coreceptor usage of
circulating viruses, leading to the suppression of ×4 strains.
© 2006 Published by Elsevier Inc.Keywords: Structured treatment interruption; HIV-1; Envelope gene; Antiretroviral resistanceIntroduction
Notorious for its genetic diversity, the HIV-1 genome
generates all possible mutations on a continuous basis. This
occurs as a result of the high rates of misincorporation by the
reverse transcriptase (≈4 × 10−4 per replication cycle), the
higher levels of viral replication and the size of genome (≈1010
base pairs) (Mansky and Temin, 1995; Perelson et al., 1996).
However, the viral population that seeds a new infection is
usually highly homogeneous in both genotype and phenotype,
and infection is followed by an increase in viral genetic diversity
over time (Diaz et al., 1996; McNearney et al., 1992; Zhang et
al., 1993; Zhu et al., 1993). The envelope gene encodes a⁎ Corresponding author. Laboratório de Retrovirologia, R. Pedro de Toledo,
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doi:10.1016/j.virol.2006.04.039glycoprotein that is subjected to great selective pressure exerted
by the immune system during chronic infection (Diaz et al.,
1997; Zhang et al., 1997). The rate of evolution of this gene is
approximately 1% per year (Diaz et al., 1997; Shankarappa et al.,
1999), thereby generating the so-called viral quasispecies.
The viral phenotypes, which change during the course of
HIV-1 infection, are classified as syncytium-inducing (SI) or
non-syncytium-inducing (NSI) (Cheng-Mayer et al., 1990).
There is a correlation between the phenotype, cytopathoge-
nicity and cell tropism. The NSI phenotypes typically bind
to the CCR5 chemokine receptors and present tropism for
macrophages and monocytes, whereas SI phenotypes bind to
CXCR4 and present tropism for lymphocytes (Roos et al.,
1992; Zhu et al., 1993). The NSI phenotypes are present
during primary infection and are less cytopathic, whereas SI
phenotypes present greater potential for in vitro cell
destruction and emerge over the course of infection (Koot
et al., 1996; Shankarappa et al., 1999). Some authors have
Fig. 1. HMA of pre-STI (week 0) and post-STI (week 12 of STI) samples from
each patient. Molecular weight markers (labeled λ) are shown in the left-hand
lanes of first and last gels.
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phenotypes and disease progression (Koot et al., 1996;
Shankarappa et al., 1999). The phenotype change requires
mutation in the env gene. A change in the V3 loop amino
acid charge from neutral or negative (D or E) to positive (R
or K) at positions 306 or 320 leads the HIV-1 phenotype to
change from NSI to SI (Fouchier et al., 1992).
The use of antiretroviral therapy leads to selective pressure
similar to that exerted by the immune system. Because
antiretroviral-resistant mutant viral strains are preexisting,
subinhibitory levels of drugs increase the risk that such strains
will be selected. In these cases, an accumulation of resistance
mutations is followed by a decrease in the pharmacological
activity of antiretroviral agents (Coffin, 1995; Larder and
Kemp, 1989).
Resistance mutations also lead to a decrease in the replicative
fitness of the virus (Goudsmit et al., 1997; Maeda et al., 1998;
Martinez-Picado et al., 2000). In the absence of antiretroviral
agents, the fitness of the wild-type virus is usually superior to
that of the antiretroviral-resistant mutant virus. This phenom-
enon allows the reemergence of the wild-type virus in patients
with resistant strain subjected to antiretroviral interruption. In
studies of structured antiretroviral interruption (STI) in patients
with virological failure, increased viral load and decreased CD4
counts have been observed simultaneous to the reversion of the
antiretroviral resistance mutations (Deeks et al., 2001; Miller et
al., 2000). In the present study, we analyzed the genetic
diversity of the HIV-1 gp120 V3 env region in chronically
infected patients subjected to a 12-week STI.
Results
Genetic characterization of HIV-1 populations
Proviral HIV-1 samples obtained from a group of 27
individuals subjected to an STI were screened by HMA. An
intra-sample HMA was performed to evaluate the diversity
within the quasispecies of each individual (Fig. 1). The PCR
input, as estimated by end-point PCR and by real-time PCR
DNA proviral load, was at least 50 copies (data not shown). We
used the following definition criteria: sample showing only one
band (homoduplex) was interpreted as having low diversity,
reflecting a relative homogeneity of the proviral population; and
sample showing a confluence of bands inferring more complex
proviral quasispecies. According to these criteria, pre- and post-
STI samples were analyzed, and the 27 individuals were divided
into four groups: group 1 (patients 01, 07, 09, 13, 15, 20, 22 and
23), presenting little pre- or post-STI genetic diversity; group 2
(patients 03, 08, 19, 24 and 26), presenting high pre-STI but low
post-STI genetic diversity; group 3 (patients 02, 04, 05, 10 and
25), presenting low pre-STI but high post-STI genetic diversity;
and group 4 (patients 06, 12, 14, 16, 17, 18, 21, 27 and 28),
presenting high pre- and post-STI genetic diversity. One patient
from group 1 (patient 01), two from group 2 (patients 03 and 19)
and two from group 3 (patients 04 and 05) were selected and
subjected to a quasispecies analysis by proviral DNA genomic
sequencing of the C2-V3-C3 gp120 region of the env gene.Virologic and immunologic markers during STI
The 27 patients were experienced in all three classes of
antiretrovirals, with a median of 8.9 prior ARV, ranging from 6
to 13. The median baseline HIV-1 RNAwas 3.97 log10 copies/
mL, and the median baseline CD4+ cell count of 224 cells/mm3.
Our results demonstrated an average reduction in CD4+ T cell
count of 95 cells and an average increase of 0.64 log10 in viral
load, after 12 weeks of STI. Our results demonstrated an
average reduction in T CD4+ of 95 cells and an average increase
of 0.64 log10 in viral load, after 12 weeks of STI. The CD4+ T
cell counts and plasma HIV-1 viral loads during STI were
studied in detail for five patients (patients 01, 03, 04, 05 and 19),
and the results are depicted in Fig. 2. There was an increase in
viral load and a decrease in CD4+ Tcell count after the 12-week
STI in patients 01, 05 and 19. No significant viral load increase
was seen in patients 03 and 04 (less than 0.5 log10 increase),
although a significant decrease in CD4 count was documented.
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The evolution of the resistance mutation profile is depicted in
Fig. 2. We generated pol sequences from plasma RNA and
proviral DNA for all patients and there was a concordance in the
resistance profile in both plasma and PBMCs either before or
after STI. We did not observe mixed HIV populations in the
resistance-related codons in any patient either before or after
STI in plasma or PBMCs. Overall, resistance codons were
replaced by wild-type codons, with the exception of the primary
mutations in patient 19.
Genetic diversity of the C2-V3-C3 region
For each one of the five patients (patients 01, 03, 04, 05 and
19), we evaluated genetic diversity in the proviral quasispecies
present in the pre- and post-STI samples. In samples from
patients 01, 03 and 05, there were strong correlations between
the HMA-inferred genetic diversity values and those measured
by sequencing. The genetic diversity of clones found in pre-STI
patient 01 samples (01A samples) was 0.00623 versus 0.00459
for those found in post-STI samples (01M samples). The dN/dS
ratio for all patient 01 clones, according to the selected
Goldman–Yang model (M0), was 0.1973, and there were no
sites under positive selective pressure. For patient 03, genetic
diversity of clones in the pre-STI samples (03A samples) was
0.05896, compared with 0.02942 for post-STI sample (03M
sample) clones and 0.05182 for all clones combined. For this
patient (patient 03), the M2 model was the best fit, and residues
291, 300, 302, 304, 320, 325 and 329 presented dN/dS ratios
>1 (Fig. 3). There was no positive selection found in residues
of patient 04 samples, in which the genetic diversity was
0.0107 in pre-STI samples (04A samples), 0.00791 in post-STI
samples (04J samples) and 0.00959 on average. According to
the Goldman–Yang model (M0), the mean dN/dS ratio in
patient 04 samples was 0.4987. In patient 05 samples, the
genetic diversity of clones was higher in post-STI samples (05L
samples). Clones found in pre-STI patient 05 samples (05A
samples) presented a genetic diversity of 0.0179 versus 0.0812
for those in post-STI samples (05L samples) and 0.0422 for all
clones combined. For this patient (patient 05), M2 was
selected, and we found dN/dS ratios >1 in residues 304, 306,
319, 321, 324, 345, 352, 353, 354, 356 and 359 (Fig. 3). The
highest number of residues under positive selective pressure
was found in patient 19 samples. For the quasispecies in
PBMCs, we found a genetic diversity of 0.0363 for the pre-STI
clones (in 19A samples), and 0.0312 for clones post-STI (19H
samples). For quasispecies in plasma, we found the genetic
diversity to be 0.0277 for clones in pre-STI samples (19Ar
samples), 0.0194 for clones in samples collected after 1 week
of STI (19Br samples) and 0.0482 for clones in post-STI
samples (19Hr samples). According to the model M3, this
patient (patient 19) presented high numbers of residues under
positive selective pressure. In patient 19 PBMC samples,
residues 278, 291, 293, 297, 334, 335, 338, 349, 351, 352 and
359 presented dN/dS ratios >1, and the majority of those
residues (residues 278, 293, 334, 335, 338, 349, 352, 353 and359) also presented dN/dS ratios >1 in patient 19 plasma
samples.
Phylogenetic and coalescent analysis
In an attempt to better clarify the clustering pattern and the
ancestral recrudescence, we performed phylogenetic and
coalescent analyses. The sequences collected pre-STI were
identified by grey circles, the sequences from post-STI were
identified by black circles. The maximum likelihood trees
constructed with the gp120 V3 env region of patients 03, 05 and
19 showed a similar topology clustering the sequences in two
distinct groups (Figs. 4–6). The clustering pattern was strongly
related to the STI status of sequences, in this way sequences
from pre-STI clustered in a group whereas sequences from post-
STI cluster in another distinct group. Because this bipolarity of
the pre- and post-STI sequences was consistently observed in
patients 03, 05 and 19, we then rooted the trees at the midpoint
root that most likely will represent the ancestor of all sequences
for each patient. This temporal pattern of the trees allowed us to
estimate the distance of each cluster to the root. The post-STI
clusters (cluster M in patient 03, cluster I in patient 05 and
clusters GW1 and GW2 in patient 19) were located closer to the
midpoint root whereas the pre-STI clusters (cluster A in patients
03 and 05 and cluster GG in patient 19) were generally located
farther from the root. Additionally, the branch length leading to
the root of post-STI clusters was shorter than the length of pre-
STI clusters. In details, for patient 03 the branch length of the
cluster M (pos-STI) was 0.00862 (±0.002) whereas the branch
length of the cluster A (pre-STI) was 0.03341 (±0.005) (Fig. 4).
For patient 05, the branch length of cluster I (post-STI) was
0.03155 (±0.0034) and for cluster A (pre-STI) it was 0.05178
(±0.004). Finally, for patient 19 the branch length of the clusters
GW 1 and GW 2 (post-STI) was 0.01323 (±0.007) and 0.03881
(±0.006), respectively, whereas the branch length of the cluster
GG (pre-STI) was 0.10195 (±0.002). The above results showed
steadily that the post-STI sequences diversified less than pre-
STI sequences from the midpoint root.
To give more strength to our hypothesis of recrudesce of
ancient variants, we used the coalescent approach to estimate
“age” of the clusters. This analysis revealed that the clusters
formed by post-STI sequences had reduced coalescent time
intervals compared to those estimated for the clusters formed by
pre-STI sequences. For patient 03, for example, the coalescent
time interval for the cluster M was 0.025 substitutions whereas
for the cluster A it was four times longer; 0.10 substitutions
(Fig. 4, panels A and B, respectively). Likewise, for patient 05/
cluster I, the coalescent time interval was 0.02 and there was no
evidence of population growth, whereas for the cluster A the
coalescent time interval was five times longer; 0.10 substitu-
tions (Fig. 5, panels A and B, respectively). For patient 19, the
coalescent time interval for clusters GW 1 and GW 2 was 0.04
and for the cluster GG was 0.05 (Fig. 6, panels A–C). These
results revealed that clusters formed by post-STI sequences had
shorter coalescent time interval than those observed in clusters
formed by pre-STI sequences. Therefore, implying that even
without assuming a midpoint root, the clusters of post-STI
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the post-STI sequences are older than the pre-STI sequences.
Data for patients 1 and 4 are not presented due to the relative
homogeneity of their sequences pre- and post-STI.
Discussion
In this study, we analyzed the genetic diversity of chronically
HIV-1-infected patients failing antiretroviral therapy and sub-
jected to STI. The preliminary analysis using HMA revealed no
defined pattern of env evolution after antiretroviral interruption.
It is interesting to note that, despite the selective pressure
imposed by antiretroviral therapy, genetic diversity can vary
widely in this gene. In addition, after interruption of the selective
pressure exerted by the antiretroviral agents, there is a change in
the genetic complexity of the gp120 V3 region of viruses over a
short period of time in 17 out of 27 individuals, favoring either
the increase or decrease of the genetic diversity of the virus.
There have been few studies analyzing the impact of STI on
genes other than pol (Kijak et al., 2002). Studies of the use of STI
in patients failing antiretroviral therapy have shown that this
strategy leads to an increase in viral load and a decrease in CD4Fig. 2. HMA genetic diversity (left), resistance mutation codons (middle) and viral loa
acid substitutions are represented as single letter codes. Letters in black indicate wild
loads are shown on the left, whereas CD4 counts are shown on the right.counts, as well as rapid replacement of viruses presenting
resistance mutations in the pol gene by wild-type viruses (Deeks
et al., 2001; Miller et al., 2000). These emerging wild-type
viruses probably represent viral populations archived in
reservoirs or sanctuaries and emerge due to their higher fitness
in the absence of antiretroviral agents. Another related issue that
needs to be taken into consideration is genomic recombination.
One hypothesis is that despite the pol profile, the more highly
adapted env should prevail. If this is true, recombination would
result in the current env profile being maintained, even with the
post-STI emergence of wild-type pol profile.
In order to make a more detailed evaluation, we used end-
point PCR to analyze the genetic profile of pre- and post-STI
viral strains by sequencing clones amplified from samples
obtained from five patients. As an initial screening method,
HMAwas used. Although not highly specific, HMA allows the
rapid and inexpensive analysis of a large number of samples and
has primarily been used for these applications (Delwart et al.,
1993; Diaz et al., 1995; Long et al., 2000). Indeed, we found an
interesting lack of concordance between the two methods in
some of the five cases in which sequencing was performed. As
mentioned earlier, in samples from patients 01, 03 and 05, thered/CD4 variation during the STI (right) for patients 01, 03, 04, 05 and 19. Amino
-type viruses and letters in gray indicate mutant viruses. Along the y axis, viral
Fig. 2 (continued).
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inferred by HMA and those measured by sequencing. In the
HMA, samples from patient 01 presented low genetic complex-
ity before and after STI, which was in agreement with the
sequencing results showing genetic diversity to be 0.32% in the
pre-STI sample and 0.62% in the post-STI sample. The same
occurred in patient 03 samples, which presented high pre-STI
genetic diversity and low post-STI genetic diversity in the HMA,which were 5.9% and 2.9%, respectively, in the sequencing. In
the HMA, patient 05 samples presented low pre-STI genetic
diversity and high post-STI genetic diversity, which were 1.8%
and 8.1%, respectively, in the sequencing. However, samples
from patients 04 and 19 presented genetic diversity values
obtained through the use of the two methodologies that initially
seem to be unrelated. The HMA of patient 04 samples classified
the clones as presenting low pre-STI and high post-STI genetic
Fig. 3.
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Fig. 3. Amino acid sequence alignments for the five patients analyzed. On the right, the genetic diversity (GD) found in pre-STI samples, 1 week of STI (for patient 19) and 12
weeks of STI (post-STI) is shown. The dN/dS ratios andmodel used for each estimation are indicated. Pre-STI sequences are at the top of the alignment, and post-STI sequences
are at the bottom. Samples are labeledwith a number representing the number of the clone generated by end-point PCR.All positive PCR cloneswere sequenced and included in
this analysis. The sequence at the top is the consensus sequence for the quasispecies found in the samples obtained from each patient. Dots indicate similarities, whereas dashes
indicate the absence of amino acids. The V3 loop, between the two cysteines, is indicated by the break in the upper line. In the alignment, positions 306 and 320, which predict
viral phenotype, aremarked in bold. For patient 19, alignments at the top are fromRNA sequences, whereas the corresponding alignments at the bottom are from proviral DNA.
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for the same samples, genetic diversity was low in pre- and post-
STI samples (1.1% and 0.8%, respectively). Careful examina-
tion of the HMA of the post-STI sample revealed that there was
only one heteroduplex band presenting slow migration rather
than the smear of heteroduplexes closer to the homoduplexes
seen in the other high genetic complexity samples. Interestingly,
as seen in Fig. 3, the quasispecies infecting this patient presented
sequences with a deletion. The HMA showed that this deletion,
although not influencing the amount of genetic diversity
calculated from the sequences, resulted in anomalous annealing,
which in turn led to slower migration of the heteroduplexes. In
the HMA of patient 19 samples, we found high initial genetic
diversity and low final genetic diversity, whereas the sequencing
revealed 3.6% and 3.1%, respectively. Although there was a
discrete decrease in post-STI genetic diversity, we considered
genetic diversity to be high at both time points. This patient was
especially interesting because, in addition to the conflict
between HMA and sequencing results, there was also a
significant increase in viral load and a decrease in the CD4count, despite the fact that the wild-type virus did not emerge
after STI. The pol gene mutations led to a high level of genotypic
antiretroviral resistance. After STI, the patient did not revert to
wild type, either at the provirus (PBMC) or virion (plasma) level.
All other patients reverted to wild-type mutations after STI, and
the pol provirus profile of patient 19 was similar to that found in
the plasma of all patients (data not shown). These results
motivated us to evaluate this patient in greater detail. To that end,
we analyzed the V3 quasispecies viruses present in plasma and
included one sample obtained after 1 week of STI.
The sequence analysis produced very interesting results.
Patient 01 did not present any change in the env sequence profile
after STI, despite the changes presented in the pol gene. The
proviral population remained homogeneous with extremely low
selective positive pressure, denoting the low immune pressure
exerted by this antigenic stimulus (Fig. 3). The results from
patient 04 are similar to those obtained for patient 01. In contrast,
patient 03 samples presented a significant post-STI decrease in
genetic diversity. It is of note that the majority of pre-STI strains
presented characteristics consistent with ×4 strains (SI
Fig. 4. Maximum likelihood tree and coalescent intervals of gp120 V3 env region of patient 03. The STI status of the sequences are identified with circles: sequences
isolated from the pre-STI time point are grey circles, whereas sequences obtained from the post-STI time point are black circles. The tree was rooted at its midpoint; the
topology clustered the sequences in two distinct groups, labeled as clusters A and M. The cluster A includes most of pre-STI sequences whereas cluster M includes
most of Post-STI sequences. Numbers above the branches are length of clusters to the root. To the right side of the tree, the panels describe the Bayesian skyline plot
depicting the coalescent intervals of each cluster. The x axis is in units of time (substitutions). The y axis represents the effective population size. Hence, panel A is the
coalescent interval of cluster M and panel B is the coalescent interval of the cluster A.
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positive charges at position 306 or 320 of the V3 loop (R or K).
After STI, these strains were replaced by strains presenting
amino acids with neutral charges at position 306 (S) or negative
charges at position 320 (E), which is typical of R5 NSI strains
(Fouchier et al., 1992). It is recognized that ×4 strains do not
usually appear in the early stages of HIV-1 infection, typically
arising and replacing the R5 strains in the advanced stages of the
disease. We therefore believe that this patient was in the
advanced stages of the disease when antiretroviral therapy was
started, and that, after STI, there was a reemergence of strains
that had been present in the early stages of the disease, together
with the reemergence of wild-type pol gene. In addition,
selective pressure, as inferred by the dN/dS ratios, was high in
the strains found in patient 03 samples.
More interesting still is the phenomenon seen in patient 05.
As seen in patient 03 samples, the pre-STI patient 05 samples
presented exclusively ×4 strains (R at position 306), and the
post-STI patient 05 samples presented a mixed population of
×4 and R5 strains in similar proportions, some strains
maintaining a positive charge at position 306 and others
maintaining a neutral charge at this position. This mixed viral
population was also responsible for the increase in genetic
diversity in the post-STI sample. In this patient, selective
pressure was also high, as evidenced by the high rates of non-synonymous substitutions, which sustained the high dN/dS
ratio. It is likely that recombination is the mechanism by which
the more recent (×4) strains coexist with the more ancient,
reemerged (R5) strains. This scenario was repeated in the case
of patient 19. The phenomenon was more pronounced from
the sequencing of virus samples obtained as actively
replicating virions that were shed in the blood stream. The
pre-STI strains were ×4 strains, presenting K at positions 306
and 320, and these strains were replaced by R5 strains
presenting neutral (S) amino acids at position 306, or negative
(E) amino acids at position 320 after STI. In addition, pre-STI
strains presented a GGGR motif at the tip of the V3 loop,
which was replaced by a GWGR motif after STI. It is known
that GWGR is the typical motif found in a proportion of
Brazilian clade B strains (Hendry et al., 1996; Morgado et al.,
1994), and that, due to the instability of the tryptophan in this
position, this motif tends to disappear over the course of HIV
infection. Tryptophan is typically replaced by amino acids,
such as glycine, that are genetically closer to tryptophan. The
reemergence of strains with the GWGR motif provides further
evidence that the more recent strains were replaced by older
strains. As previously mentioned, although patient 19 was the
only patient that did not revert the antiretroviral resistance-
related viral mutations to wild type, either in the plasma or in
the PBMC, there was a significant increase in viral load after
Fig. 5. Maximum likelihood tree and coalescent intervals of gp120 V3 env region of patient 05. The STI status of the sequences are identified with circles: sequences
isolated from the pre-STI time point are grey circles, whereas sequences obtained from the post-STI time point are black circles. The tree was rooted at its midpoint; the
topology clustered the sequences in two distinct groups, labeled as clusters A and I. The cluster A includes most of pre-STI sequences whereas cluster I includes most
of Post-STI sequences. Numbers above the branches are length of clusters to the root. To the right side of the tree, the panels describe the Bayesian skyline plot
depicting the coalescent intervals of each cluster. The x axis is in units of time (substitutions). The y axis represents the effective population size. Hence, panel A is the
coalescent interval of cluster A and panel B is the coalescent interval of the cluster I.
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resistance due to the presence of resistance mutations, these
medications might have a residual antiretroviral effect on viral
suppression.
It is also of note that, after STI, CD4 counts did not always
change in ways that were proportional to post-STI changes in
viral loads. In patients 03 and 04, there was no significant
increase in viral loads after 12 weeks of STI, although CD4
counts decreased by more than 50%. The unique feature in these
two cases was the reemergence of the wild-type strains. In both
of these cases, there was an increase in viral activation after STI
(data not shown). One could therefore speculate that the
massive cell destruction was related to the cell activation caused
by the emergence of wild-type viruses and not to the direct
cytopathic effect of the high viral loads (Smith et al., 2002).
One possible limitation of our study is the fact that we
analyzed the provirus quasispecies rather than the viral
quasispecies. Indeed, RNA analysis could have increased the
sensitivity to the more dynamic changes in the viral quasis-
pecies, such as those seen in patient 19 samples. However, our
focus was the impact of these changes on the cellular reservoir of
these patients. Studies of HIV-1 dynamics have indicated that
because the half-life of more than 99% HIV-infected cells is
approximately 2.4 days, the time required to seed the cell
reservoir is extremely short (Ho, 1995; Wei et al., 1995).Our study therefore provides unique and interesting insights
into aspects of the dynamics of HIV-1 viral replication in
humans. We demonstrated that the dramatic disturbance caused
by the interruption of antiretroviral therapy results in the
activation of old progenies that are able to repopulate the
patient's cell reservoir. However, there were two patients in
whom this phenomenon was not observed. These two patients
presented highly homogeneous sequences and low immune
selective pressure, as inferred by the dN/dS ratios <1. We have
developed three separate hypotheses regarding these two cases.
First, these patients might have been treated early, before
significant genetic diversity was acquired, thereby presenting
only one viral profile in the quasispecies. Second, as has
previously been suggested (Wolinsky et al., 1996), low
selective pressure due to a weak immune system might have
precluded the generation of significant genetic diversity, again
resulting in a single viral profile. Third, as proposed by Costa
et al. (2004), because the change in the pol profile in these two
cases suggested that the best adapted env profile to the patient
at this time would be the current one, recombination might
have maintained the genetic env profile after STI. Indeed, there
is some evidence that recombination may have occurred in
patient 05. In patient 05 samples, we detected two distinct viral
populations after STI: one being a more ancient, emerging
population; and the other presenting similar proportions of
Fig. 6. Maximum likelihood tree and coalescent intervals of gp120 V3 env region of patient 19. The STI status of the sequences are identified with circles: sequences
isolated from the pre-STI time point are grey circles, sequences obtained 1 week after STI are white circles and sequences obtained 12 weeks after STI are black circles.
The tree was rooted at its midpoint; the topology clustered the sequences in two distinct groups, labeled as clusters GG (presenting the motif GGGR at the tip of the V3
loop) and GW (GW 1 and GW 2, presenting the GWGR motif at the tip of the V3 loop). The cluster GG includes most of pre-STI sequences whereas cluster GW
includes most of post-STI sequences. Numbers above the branches are length of clusters to the root. To the right side of the tree, the panels describe the Bayesian
skyline plot depicting the coalescent intervals of each cluster. The x axis is in units of time (substitutions). The y axis represents the effective population size. Hence,
panels A and B are the coalescent interval of cluster GW 1 and GW 2, respectively, and panel C is the coalescent interval of the cluster GG.
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some of the mechanisms involved in viral evolution, in which
selective pressure is applied not only by the immune system
but also by antiretroviral therapy. Therefore, one outcome of
STI for patients could be the impact on the coreceptor usage
of circulating viruses, leading to the suppression of ×4
strains.
Methods
Sample collection
Samples to be analyzed were collected from 27 chronically
infected patients who had experienced antiretroviral therapy
failure and were subjected to an STI at the Universidade Federal
de São Paulo, Brazil, between June 1999 and June 2000. Allsamples were obtained from peripheral blood mononuclear cells
(PBMCs), except for select samples obtained from an individual
patient, which were derived from plasma.
Nucleic acid purification
The HIV-1 proviral DNA was extracted from buffy coats
using the QIAamp DNA Blood Mini Kit (Qiagen Inc., Santa
Clarita, CA), and viral RNAwas purified from plasma using the
QIAamp viral RNA kit (Qiagen) according to the manufacturer
instructions.
cDNA synthesis
Following RNA viral denaturation at 70 °C for 10 min,
cDNA synthesis was performed at 42 °C for 90 min using a
45W.P. Silva et al. / Virology 354 (2006) 35–47reverse transcriptase enzyme (20 U Super Script TM II; Gibco
BRL-Life Technologies, Rockville, MD).
Nested PCR amplification
A C2-V3-C3 region 300-bp fragment (designated V3 for the
sake of simplicity) was amplified using nested PCR as
previously described (Wolfs et al., 1991). For the pol gene
amplification, we used a nested PCR as previously described
(Sucupira et al., 2001).
Heteroduplex mobility analysis
After PCR amplification, samples were screened using
heteroduplex mobility analysis (HMA) (Delwart et al., 1993).
The V3 PCR products were denatured at 94 °C for 2 min, chilled
on ice and subjected to electrophoresis on a polyacrylamide gel
as previously described (Diaz et al., 1999).
End-point PCR
The strategy for generating PCR clones was based on serial
dilutions of DNA samples. An aliquot of the last dilution in
which there was positive amplification was added to a PCR
mixture (total volume of 1 mL), which was then divided among
20 reaction tubes (50 μL per tube). If the number of positive
amplifications was that expected from the Poisson distribution
(the probability of each amplification event starting from a
single template and inversely proportional to the number of
events), the positive amplification products were considered
clones (Diaz et al., 1995; Simmonds et al., 1990).
DNA sequencing
The PCR products were purified using the QIAquick PCR
Purification Kit” (Qiagen Inc., Chatsworth, CA) according to
manufacturer instructions.
Sequencing was performed using the Thermo Sequenase
Fluorescent-labeled primer cycle sequencing kit (RPN 2436;
Amersham Pharmacia Biotech UK Limited, Buckinghamshire,
England), and primers were labeled with CY5.5. Electropho-
resis was performed using the Long Reader Tower (Bayer
Corp., Berkeley, CA).
Predicting the HIV-1 phenotype
The env sequences corresponding to the V3 loop region were
used to predict the coreceptor use and the viral phenotype based
on the presence of residues at positions 306 and 320 in the V3
loop (Chesebro et al., 1991; De Jong et al., 1992; Milich et al.,
1993).
Genetic diversity
Patient sequences were aligned by eye using the SeaView
(Galtier et al., 1996). The Modeltest program (Posada and
Crandall, 1998) was used to select maximum likelihood modelsof nucleotide substitutions for each alignment, and corrected
distance matrices were then built using the PAUP* program
[Swofford, DL (2002) PAUP*; Phylogenetic analysis using
parsimony (*and other methods), Version 4; Sinauer Associates,
Sunderland, MA]. Genetic diversity was calculated as
d Rijpij=nc;
where p is the corrected distance between sequences i and j, and
nc is the total number of sequence comparisons among n
sequences (Nei, 1987):
nc nn 1=2:
Selection pressures
Evidences that support selective pressure on the V3 region
comes from the analysis of the dN/dS ratio of sequence pairs,
where dN is the observed frequency of non-synonymous
substitution per replacement site, and the dS is the observed
frequency of synonymous substitution per silent site. The higher
the dN/dS ratio (>1), the stronger the selective pressure for
amino acid change. Phylogenetic trees for each patient were
inferred by maximum likelihood using the PAUP* program, and
for each alignment and correspondent tree, three models of
codon substitution were compared using a likelihood ratio test
(LRT) using CODEML as implemented in the PAML package
[Yang, 1997; Phylogenetic Analysis by Maximum Likelihood
(PAML), Version 1.4. department of Integrative Biology,
University of California, Berkeley]. The first model, M0,
assumes that all codons fall into a single category of sites with
fixed non-synonymous to synonymous substitutions (dN/dS)
ratios (Goldman and Yang, 1994). The second model, M1,
assumes a class of conserved sites with dN/dS ratios equals 0
and a class of neutral sites with dN/dS = 1. The third model, M2,
comprises the categories used in the second model and adds an
additional category of positively selected sites with dN/dS >1
(Nielsen and Yang, 1998). An LRT was performed to compare
the M0 and M1 models. When M1 was chosen, another LRT
was applied to compare it with M2. When M2 was chosen,
positively selected sites were identified by their posterior
probabilities, as calculated by CODEML, of belonging to the
class of sites presenting dN/dS ratios >1.
Alignment and phylogenetic inference
The sequences were manually aligned using the SE-AL
program (Version 2.0; Department of Zoology, Oxford Univer-
sity [http://evolve.zoo.ox.ac.uk/software/]). Phylogenetic infer-
ences were made using gp120 V3 env region of HIV-1.
Maximum likelihood trees were done by first determining
the most appropriate model of nucleotide substitution for each
data set, according to a hierarchical likelihood ratio test
(hLRT), as implemented in the program Modeltest v3.06
(Posada and Crandall, 1998). The most appropriate evolutive
model was used to obtain the initial trees through the neighbor-
joining method; the resulting trees were then swapped by the
46 W.P. Silva et al. / Virology 354 (2006) 35–47nearest-neighbor interchange method (NNI). All phylogenetic
inferences were done using the program PAUP*. To the
coalescent analysis, we used the reversible jump Markov chain
Monte Carlo method (Opgen-Rhein et al., 2005) as is
implemented in the “ape” library of the R-package (http://
www.r-project.org).
Acknowledgments
This study received financial support from the Fundação de
Amparo à Pesquisa do Estado de São Paulo (FAPESP,
Foundation for the Support of Research in the State of São
Paulo; grant number: 98/14381-4).
References
Cheng-Mayer, C., Quiroga, M., Tung, J.W., Dina, D., Levy, J.A., 1990. Viral
determinants of human immunodeficiency virus type 1 T-cell or macrophage
tropism, cytopathogenicity, and CD4 antigen modulation. J. Virol. 64 (9),
4390–4398.
Chesebro, B., Nishio, J., Perryman, S., Cann, A., O'Brien, W., Chen, I.S.,
Wehrly, K., 1991. Identification of human immunodeficiency virus envelope
gene sequences influencing viral entry into CD4-positive HeLa cells, T-
leukemia cells, and macrophages. J. Virol. 65 (11), 5782–5789.
Coffin, J.M., 1995. HIV population dynamics in vivo: implications for genetic
variation, pathogenesis, and therapy. Science 267 (5197), 483–489.
Costa, L.J., Mayer, A.J., Busch, M.P., Diaz, R.S., 2004. Evidence for
selection of more adapted human immunodeficiency virus type 1
recombinant strains in a dually infected transfusion recipient. Virus
Genes 28 (3), 259–572.
De Jong, J.J., De Ronde, A., Keulen, W., Tersmette, M., Goudsmit, J., 1992.
Minimal requirements for the human immunodeficiency virus type 1 V3
domain to support the syncytium-inducing phenotype: analysis by single
amino acid substitution. J. Virol. 66 (11), 6777–6780.
Deeks, S.G., Wrin, T., Liegler, T., Hoh, R., Hayden, M., Barbour, J.D.,
Hellmann, N.S., Petropoulos, C.J., McCune, J.M., Hellerstein, M.K., Grant,
R.M., 2001. Virologic and immunologic consequences of discontinuing
combination antiretroviral-drug therapy in HIV-infected patients with
detectable viremia. N. Engl. J. Med. 344 (7), 472–480.
Delwart, E.L., Shpaer, E.G., Louwagie, J., McCutchan, F.E., Grez, M.,
Rubsamen-Waigmann, H., Mullins, J.I., 1993. Genetic relationships
determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env
genes. Science 262 (5137), 1257–1261.
Diaz, R.S., Sabino, E.C., Mayer, A., Mosley, J.W., Busch, M.P., 1995. Dual
human immunodeficiency virus type 1 infection and recombination in a
dually exposed transfusion recipient. The Transfusion Safety Study Group.
J. Virol. 69 (6), 3273–3281.
Diaz, R.S., Sabino, E.C., Mayer, A., deOliveira, C.F., Mosley, J.W., Busch,
M.P., 1996. Lack of dual HIV infection in a transfusion recipient exposed
to two seropositive blood components. AIDS Res. Hum. Retrovir. 12 (13),
1291–1295.
Diaz, R.S., Zhang, L., Busch, M.P., Mosley, J.W., Mayer, A., 1997.
Divergence of HIV-1 quasispecies in an epidemiologic cluster. AIDS 11
(4), 415–422.
Diaz, R.S., De Oliveira, C.F., Pardini, R., Operskalski, E., Mayer, A.J., Busch,
M.P., 1999. HIV type 1 tat gene heteroduplex mobility assay as a tool to
establish epidemiologic relationships among HIV type 1-infected indivi-
duals. AIDS Res. Hum. Retrovir. 15 (13), 1151–1156.
Fouchier, R.A., Groenink, M., Kootstra, N.A., Tersmette, M., Huisman, H.G.,
Miedema, F., Schuitemaker, H., 1992. Phenotype-associated sequence
variation in the third variable domain of the human immunodeficiency virus
type 1 gp120 molecule. J. Virol. 66 (5), 3183–3187.
Galtier, N., Gouy, M., Gautier, C., 1996. SEAVIEW and PHYLO_WIN: two
graphic tools for sequence alignment and molecular phylogeny. Comput.
Appl. Biosci. 12 (6), 543–548.Goldman, N., Yang, Z., 1994. A codon-based model of nucleotide substitution
for protein-coding DNA sequences. Mol. Biol. Evol. 11 (5), 725–736.
Goudsmit, J., de Ronde, A., de Rooij, E., de Boer, R., 1997. Broad spectrum of
in vivo fitness of human immunodeficiency virus type 1 subpopulations
differing at reverse transcriptase codons 41 and 215. J. Virol. 71 (6),
4479–4484.
Hendry, R.M., Hanson, C.V., Bongertz, V., Morgado, M., Duarte, A., Casseb, J.,
Brigido, L., Sabino, E., Diaz, R., Galvao-Castro, B., 1996. Immunoreac-
tivity of Brazilian HIV isolates with different V3 motifs. Mem. Inst.
Oswaldo Cruz 91 (3), 347–348.
Ho, D.D., 1995. HIV-1 dynamics in vivo. J. Biol. Regul. Homeostatic Agents 9
(3), 76–77.
Kijak, G.H., Simon, V., Balfe, P., Vanderhoeven, J., Pampuro, S.E., Zala, C.,
Ochoa, C., Cahn, P., Markowitz, M., Salomon, H., 2002. Origin of human
immunodeficiency virus type 1 quasispecies emerging after antiretroviral
treatment interruption in patients with therapeutic failure. J. Virol. 76 (14),
7000–7009.
Koot, M., van 't Wout, A.B., Kootstra, N.A., de Goede, R.E., Tersmette, M.,
Schuitemaker, H., 1996. Relation between changes in cellular load,
evolution of viral phenotype, and the clonal composition of virus
populations in the course of human immunodeficiency virus type 1
infection. J. Infect. Dis. 173 (2), 349–354.
Larder, B.A., Kemp, S.D., 1989. Multiple mutations in HIV-1 reverse
transcriptase confer high-level resistance to zidovudine (AZT). Science
246 (4934), 1155–1158.
Long, E.M., Martin, H.L., Kreiss Jr., J.K., Rainwater, S.M., Lavreys, L.,
Jackson, D.J., Rakwar, J., Mandaliya, K., Overbaugh, J., 2000. Gender
differences in HIV-1 diversity at time of infection. Nat. Med. 6 (1), 71–75.
Maeda, Y., Venzon, D.J., Mitsuya, H., 1998. Altered drug sensitivity, fitness,
and evolution of human immunodeficiency virus type 1 with pol gene
mutations conferring multi-dideoxynucleoside resistance. J. Infect. Dis. 177
(5), 1207–1213.
Mansky, L.M., Temin, H.M., 1995. Lower in vivo mutation rate of human
immunodeficiency virus type 1 than that predicted from the fidelity of
purified reverse transcriptase. J. Virol. 69 (8), 5087–5094.
Martinez-Picado, J., Savara, A.V., Shi, L., Sutton, L., D'Aquila, R.T., 2000.
Fitness of human immunodeficiency virus type 1 protease inhibitor-selected
single mutants. Virology 275 (2), 318–322.
McNearney, T., Hornickova, Z., Markham, R., Birdwell, A., Arens, M., Saah,
A., Ratner, L., 1992. Relationship of human immunodeficiency virus type 1
sequence heterogeneity to stage of disease. Proc. Natl. Acad. Sci. U.S.A. 89
(21), 10247–10251.
Milich, L., Margolin, B., Swanstrom, R., 1993. V3 loop of the human
immunodeficiency virus type 1 Env protein: interpreting sequence
variability. J. Virol. 67 (9), 5623–5634.
Miller, V., Sabin, C., Hertogs, K., Bloor, S., Martinez-Picado, J., D'Aquila, R.,
Larder, B., Lutz, T., Gute, P., Weidmann, E., Rabenau, H., Phillips, A.,
Staszewski, S., 2000. Virological and immunological effects of treatment
interruptions in HIV-1 infected patients with treatment failure. AIDS 14 (18),
2857–2867.
Morgado,M.G., Sabino, E.C., Shpaer, E.G., Bongertz,V., Brigido, L., Guimaraes,
M.D., Castilho, E.A., Galvao-Castro, B., Mullins, J.I., Hendry, R.M., et al.,
1994. V3 region polymorphisms in HIV-1 from Brazil: prevalence of subtype
B strains divergent fromNorthAmerican/European prototype and detection of
subtype F. AIDS Res. Hum. Retrovir. 10 (5), 569–576.
Nei, M., 1987. Molecular Evolutionary Genetics. Columbia Univ. Press,
New York.
Nielsen, R., Yang, Z., 1998. Likelihood models for detecting positively selected
amino acid sites and applications to the HIV-1 envelope gene. Genetics 148
(3), 929–936.
Opgen-Rhein, R., Fahmeir, L., Strimmer, K., 2005. Inference of demographic
history from genealogical trees using reversible jump Markov chain Monte
Carlo. BMC Evolut. Biol. 5 (6), 1–13.
Perelson, A.S., Neumann, A.U., Markowitz, M., Leonard, J.M., Ho, D.D., 1996.
HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and
viral generation time. Science 271 (5255), 1582–1586.
Posada, D., Crandall, K.A., 1998. MODELTEST: testing the model of DNA
substitution. Bioinformatics 14 (9), 817–818.
47W.P. Silva et al. / Virology 354 (2006) 35–47Roos, M.T., Lange, J.M., de Goede, R.E., Coutinho, R.A., Schellekens, P.T.,
Miedema, F., Tersmette, M., 1992. Viral phenotype and immune response in
primary human immunodeficiency virus type 1 infection. J. Infect. Dis. 165
(3), 427–432.
Shankarappa, R., Margolick, J.B., Gange, S.J., Rodrigo, A.G., Upchurch, D.,
Farzadegan, H., Gupta, P., Rinaldo, C.R., Learn, G.H., He, X., Huang, X.L.,
Mullins, J.I., 1999. Consistent viral evolutionary changes associated with the
progression of human immunodeficiency virus type 1 infection. J. Virol. 73
(12), 10489–10502.
Simmonds, P., Balfe, P., Peutherer, J.F., Ludlam, C.A., Bishop, J.O., Brown,
A.J., 1990. Human immunodeficiency virus-infected individuals contain
provirus in small numbers of peripheral mononuclear cells and at low
copy numbers. J. Virol. 64 (2), 864–872.
Smith, K.Y., Steffens, C.M., Truckenbrod, A., Landay, A., Al-Harthi, L., 2002.
Immune reconstitution after successful treatment with protease inhibitor-
based and protease inhibitor-sparing antiretroviral regimens. J. Acquired
Immune Defic. Syndr. 29 (5), 544–545.
Sucupira, M.C., Souza, I.E., Costa, L.J., Scheinberg, M.A., Diaz, R.S., 2001.
Antiretroviral treatment failure and HIV-1 genotypic resistance in Sao Paulo,
Brazil, Antiviral Therapy. Antivir. Ther. 6 (4), 263–264.
Wei, X., Ghosh, S.K., Taylor, M.E., Johnson, V.A., Emini, E.A., Deutsch, P.,
Lifson, J.D., Bonhoeffer, S., Nowak, M.A., Hahn, B.H., et al., 1995. Viraldynamics in human immunodeficiency virus type 1 infection. Nature 373
(6510), 117–122.
Wolfs, T.F., Zwart, G., Bakker, M., Valk, M., Kuiken, C.L., Goudsmit, J., 1991.
Naturally occurring mutations within HIV-1 V3 genomic RNA lead to
antigenic variation dependent on a single amino acid substitution. Virology
185 (1), 195–205.
Wolinsky, S.M., Korber, B.T., Neumann, A.U., Daniels, M., Kunstman, K.J.,
Whetsell, A.J., Furtado, M.R., Cao, Y., Ho, D.D., Safrit, J.T., 1996. Adaptive
evolution of human immunodeficiency virus-type 1 during the natural
course of infection. Science 272 (5261), 537–542.
Yang, Z., 1997. Phylogenetic Analysis byMaximumLikelihood (PAML), Version
1.4. Department of Integrative Biology, University of California, Berkeley.
Zhang, L.Q., MacKenzie, P., Cleland, A., Holmes, E.C., Brown, A.J.,
Simmonds, P., 1993. Selection for specific sequences in the external
envelope protein of human immunodeficiency virus type 1 upon primary
infection. J. Virol. 67 (6), 3345–3356.
Zhang, L., Diaz, R.S., Ho, D.D., Mosley, J.W., Busch, M.P., Mayer, A., 1997.
Host-specific driving force in human immunodeficiency virus type 1
evolution in vivo. J. Virol. 71 (3), 2555–2561.
Zhu, T., Mo, H., Wang, N., Nam, D.S., Cao, Y., Koup, R.A., Ho, D.D., 1993.
Genotypic and phenotypic characterization of HIV-1 patients with primary
infection. Science 261 (5125), 1179–1181.
